CR8450A - Uso extendido de combinacion que comprende estrogenos y progestinas - Google Patents

Uso extendido de combinacion que comprende estrogenos y progestinas

Info

Publication number
CR8450A
CR8450A CR8450A CR8450A CR8450A CR 8450 A CR8450 A CR 8450A CR 8450 A CR8450 A CR 8450A CR 8450 A CR8450 A CR 8450A CR 8450 A CR8450 A CR 8450A
Authority
CR
Costa Rica
Prior art keywords
strogens
progestines
combination
extended use
progestin
Prior art date
Application number
CR8450A
Other languages
English (en)
Inventor
Dusterberg Bernd
Endrikat Jan
Schurmann Rolf
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34443011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8450(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of CR8450A publication Critical patent/CR8450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una preparacion farmaceutica para obtener un tratamieno hormonal continuo durante un periodo de tiempo deseado mas prolongado que 21-28 dias, que comprende una primera composicion que contiene al menos un estrogeno y/o al menos una progestina en una cantidad predeterminada, que se adminsitra en los primeros 21-28 dias y una segunda que contiene al menos un estrogeno y/o al menos una progestina, en una cantidad predeterminada mayor que la cantidad de la primera composicion, y que comprende una secuencia mono o multifacetica de dosificaciones farmaceuticas.
CR8450A 2003-11-26 2006-06-13 Uso extendido de combinacion que comprende estrogenos y progestinas CR8450A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090405A EP1535618A1 (en) 2003-11-26 2003-11-26 Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions

Publications (1)

Publication Number Publication Date
CR8450A true CR8450A (es) 2007-06-06

Family

ID=34443011

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8450A CR8450A (es) 2003-11-26 2006-06-13 Uso extendido de combinacion que comprende estrogenos y progestinas

Country Status (22)

Country Link
US (1) US20080234240A1 (es)
EP (3) EP1535618A1 (es)
JP (1) JP2007512291A (es)
KR (1) KR20060126671A (es)
CN (1) CN1905885A (es)
AR (1) AR046671A1 (es)
AU (1) AU2004292778A1 (es)
BR (1) BRPI0416924A (es)
CA (1) CA2547051A1 (es)
CR (1) CR8450A (es)
EA (1) EA200600964A1 (es)
EC (1) ECSP066674A (es)
GT (1) GT200400242A (es)
IL (1) IL175858A0 (es)
NO (1) NO20062945L (es)
PA (1) PA8618301A1 (es)
PE (1) PE20051038A1 (es)
RS (1) RS20060348A (es)
TW (1) TW200529862A (es)
UY (1) UY28631A1 (es)
WO (1) WO2005051400A1 (es)
ZA (1) ZA200605224B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20090181075A1 (en) * 2005-07-15 2009-07-16 Gordon Ryan D Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
WO2008018872A1 (en) * 2006-08-10 2008-02-14 Drugtech Corporation Therapeutic methods of using estrogen compositions
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
CN104546870B (zh) * 2015-01-27 2018-01-12 唐凡兰 一种避孕药
UA123099C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована в порожнині рота одиниця дозування, яка містить естетрольний компонент
US20160367567A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
HRP20210668T1 (hr) 2015-06-18 2021-05-28 Estetra Sprl Orodisperzibilna tableta koja sadrži estetrol
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JP2018083806A (ja) * 2016-11-11 2018-05-31 持田製薬株式会社 月経困難症治療用組成物
CA3178181A1 (en) * 2018-02-07 2019-08-15 Estetra Srl Contraceptive composition with reduced cardiovascular effects
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CL2021001762A1 (es) * 2021-07-01 2022-01-21 Univ Pontificia Catolica Chile Uso del estetrol como tratamiento para la endometriosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969502A (en) * 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
EP0559240B1 (en) * 1987-09-24 2001-12-05 Jencap Research Limited Contraceptive packages containing oestrogen and progestin
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
DE69724796T2 (de) * 1996-07-26 2004-07-01 Wyeth Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
AU9028098A (en) 1997-08-27 1999-03-16 Ortho Pharmaceutical Corporation Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
WO2003006027A1 (en) * 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
RU2351339C2 (ru) * 2001-12-05 2009-04-10 Дюрамед Фармасьютикалс, Инк. Оральные контрацептивы для предотвращения беременности и уменьшения предменструальной симптоматики

Also Published As

Publication number Publication date
BRPI0416924A (pt) 2007-01-16
US20080234240A1 (en) 2008-09-25
ZA200605224B (en) 2009-10-28
GT200400242A (es) 2006-01-18
EP1535618A1 (en) 2005-06-01
UY28631A1 (es) 2005-06-30
ECSP066674A (es) 2006-10-25
IL175858A0 (en) 2006-10-05
PA8618301A1 (es) 2006-05-16
EP1689409A1 (en) 2006-08-16
KR20060126671A (ko) 2006-12-08
CN1905885A (zh) 2007-01-31
RS20060348A (sr) 2008-08-07
PE20051038A1 (es) 2006-02-08
NO20062945L (no) 2006-08-23
CA2547051A1 (en) 2005-06-09
AU2004292778A1 (en) 2005-06-09
AR046671A1 (es) 2005-12-14
EA200600964A1 (ru) 2006-10-27
JP2007512291A (ja) 2007-05-17
TW200529862A (en) 2005-09-16
EP2044942A1 (en) 2009-04-08
WO2005051400A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
CR8450A (es) Uso extendido de combinacion que comprende estrogenos y progestinas
CY2021020I2 (el) Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
ES2172592T3 (es) Agente antagonista de progesterona y agente gestageno para el tratamiento de la endometriosis y del liomioma uterino.
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
BR0010113B1 (pt) Preparações para uso externo na pele.
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
MX9704550A (es) Formulaciones de medicamentos en aerosol.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
ES2046083B1 (es) Procedimiento para preparar composiciones de liberacion prolongada.
HN2001000146A (es) Derivados de pirazol
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
PA8625001A1 (es) Composiciones de pelicula
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
BRPI0214716B8 (pt) kit, preparos, e uso de estrogênio e progestina na fabricação de um medicamento para uso na prevenção de gravidez
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
ATE294585T1 (de) Vorbeugung von kolorektalkrebs
BRPI0408518A (pt) terapia combinada compreendendo nemorubicin e um inibidor de ciclooxigenase-2
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
CL2023000450A1 (es) Nueva composición de anticonceptivo oral de liberación modificada

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)